ReviewOncoTargets and therapy2014

Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.

Sungkyoung Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.